Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia

Trial Details

NCT ID
NCT06451861
Phase
PHASE2
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Chidamide
  • Venetoclax
  • azacitidine
  • Anthracyclines or anthraquinones
  • cytarabine
Locations (sample)
  • Dongguan, Guangdong, China|23.01797,113.74866
  • Foshan, Guangdong, China|23.02677,113.13148
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydro…
  • Age ≥18 years old;
  • The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the inf…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →